We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Requests Suspending Sales of Hundreds of Drugs Due to Flawed Data from Indian CRO
EMA Requests Suspending Sales of Hundreds of Drugs Due to Flawed Data from Indian CRO
The EMA is recommending that the European Commission suspend the sales of more than 300 generic drug formulations that were approved from flawed bioequivalence studies conducted at two of Micro Therapeutic Research Labs’ facilities in India.